JP2009234984A - Agent for inhibition of lowering or for ameliorating renal function - Google Patents
Agent for inhibition of lowering or for ameliorating renal function Download PDFInfo
- Publication number
- JP2009234984A JP2009234984A JP2008083019A JP2008083019A JP2009234984A JP 2009234984 A JP2009234984 A JP 2009234984A JP 2008083019 A JP2008083019 A JP 2008083019A JP 2008083019 A JP2008083019 A JP 2008083019A JP 2009234984 A JP2009234984 A JP 2009234984A
- Authority
- JP
- Japan
- Prior art keywords
- renal function
- suppressing
- improving
- food
- decrease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003907 kidney function Effects 0.000 title claims abstract description 103
- 230000005764 inhibitory process Effects 0.000 title abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 16
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 61
- 230000007423 decrease Effects 0.000 claims description 54
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 36
- 229930003316 Vitamin D Natural products 0.000 claims description 19
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 19
- 235000019166 vitamin D Nutrition 0.000 claims description 19
- 239000011710 vitamin D Substances 0.000 claims description 19
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 19
- 229940046008 vitamin d Drugs 0.000 claims description 19
- 229940109239 creatinine Drugs 0.000 claims description 18
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 14
- 230000006866 deterioration Effects 0.000 claims description 14
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 10
- 229940116269 uric acid Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 7
- 241000221198 Basidiomycota Species 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 241000233866 Fungi Species 0.000 abstract 2
- 238000012360 testing method Methods 0.000 description 36
- 240000001080 Grifola frondosa Species 0.000 description 18
- 235000007710 Grifola frondosa Nutrition 0.000 description 18
- 230000006872 improvement Effects 0.000 description 16
- 208000001647 Renal Insufficiency Diseases 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 201000006370 kidney failure Diseases 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000007515 enzymatic degradation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000009534 blood test Methods 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229940067866 dandelion extract Drugs 0.000 description 1
- 235000020691 dandelion extract Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明はキノコの水性溶媒抽出物を有効成分とする腎機能の低下抑制または改善剤、腎機能の低下抑制または改善用食品に関する。 The present invention relates to an agent for suppressing or improving renal function, which comprises an aqueous solvent extract of mushrooms as an active ingredient, and a food for suppressing or improving renal function.
腎臓は成人の体重で半分以上を占める体液の出入りや流れを管理している重要な臓器である。主な働きとしては老廃物の排泄、体液のコントロール、ホルモンの分泌などが挙げられる。 The kidney is an important organ that controls the entry and exit of fluids that account for more than half of the weight of an adult. The main functions include excretion of waste products, control of body fluids, and secretion of hormones.
腎臓には大動脈から枝分かれした腎動脈を通じて血液が流れこみ、糸球体へと至る。糸球体は毛細血管の網が小さな球状になった構造体であり、ここで血液を濾過して不必要な物質と必要な物質が分けられる。糸球体に入った血液は細動脈を通って出ていき、最終的に１本の太い腎静脈を形成して血液を腎臓の外へ運び出している。 Blood flows into the kidney through the renal artery branched from the aorta and reaches the glomerulus. The glomerulus is a structure in which the network of capillaries is a small sphere, and blood is filtered here to separate unnecessary substances from necessary substances. The blood that enters the glomerulus exits through the arteriole, and finally forms a thick renal vein that carries the blood out of the kidney.
糸球体はいったんダメージを受けると再生することができないため、様々な要因で糸球体の機能が低下すると、腎臓が血液をろ過して血液中の代謝性老廃物をうまく取り除くことができなくなる。機能低下が進行し６０％以上の機能が失われた状態が腎不全である。 Since glomeruli cannot be regenerated once they are damaged, when the glomerular function decreases due to various factors, the kidneys cannot filter blood and remove metabolic waste products in the blood well. Renal failure is a state in which functional deterioration has progressed and more than 60% of the function has been lost.
腎機能は主に血液検査で調べることができる。特に血清クレアチニンと尿素窒素が指標として用いられている。クレアチニンはエネルギー産生に関わるクレアチンの分解物であり、血液を介して腎臓より尿中に排出されている。このため腎機能が低下するとクレアチニンの血中濃度が上昇することになる。一般に腎機能が正常の半分以下に低下すると血清クレアチニン濃度が上昇し始めると言われている。 Renal function can be examined mainly by blood tests. In particular, serum creatinine and urea nitrogen are used as indicators. Creatinine is a degradation product of creatine involved in energy production, and is excreted from the kidneys into urine via blood. For this reason, when renal function falls, the blood concentration of creatinine will rise. Generally, it is said that the serum creatinine concentration starts to rise when the renal function falls below half of normal.
尿素窒素も腎機能の指標として用いられているが、他の要因で増加することもあり、血清クレアチンと併せて評価される。一般的に慢性的な腎疾患の場合、腎機能が３／４程度失われてはじめて、血中尿素窒素の増加が認められるようになると言われている。 Urea nitrogen is also used as an indicator of renal function, but it may increase due to other factors and is evaluated in conjunction with serum creatine. In general, in the case of chronic kidney disease, it is said that an increase in blood urea nitrogen is observed only after about 3/4 of the kidney function is lost.
腎不全と診断された場合、大半の人で病態は進行していくため、人工透析や移植を受ける以外に治療の方法がない。また合併症を防ぐために、食事に細心の注意を払うことが必要となる。特にタンパク質の制限により腎機能の低下を遅らせることができると言われており、腎不全予備軍とされる人々にとっても食事制限が唯一の改善方法となっている。なお現在腎不全そのものを治療する医薬品は存在せず、腎不全によって引き起こされる症状を緩和させる薬を投与されているのが実状である。 When kidney failure is diagnosed, the pathology progresses in most people, so there is no treatment other than artificial dialysis or transplantation. It is also necessary to pay close attention to meals to prevent complications. In particular, it is said that protein restriction can delay the decline in kidney function, and dietary restriction is the only improvement method for people who are considered to have a renal failure reserve. Currently, there are no drugs for treating renal failure itself, and it is the reality that drugs that relieve symptoms caused by renal failure are being administered.
このような背景から、日常の食生活の中で手軽に摂取することができ、腎機能の低下を抑制する、または改善するような食品や医薬品が求められている。 From such a background, there is a demand for foods and pharmaceuticals that can be easily taken in daily eating habits, and that suppress or improve a decrease in renal function.
腎機能の低下抑制または改善効果を訴求した特許としては以下の報告がされているが、キノコの水性溶媒抽出物に腎機能改善効果があることはこれまで知られていなかった。
本発明は、腎機能の低下抑制または改善剤、腎機能の低下抑制または改善用食品を提供することを課題とする。即ち、日常の食生活を維持しながらも、併用して摂取することで、腎機能の低下抑制または改善ができる食品、医薬品、機能性食品等を提供することを目的とする。 An object of the present invention is to provide an agent for suppressing or improving the decrease in renal function and a food for suppressing or improving the decrease in renal function. That is, an object of the present invention is to provide foods, pharmaceuticals, functional foods and the like that can suppress or improve a decrease in renal function by ingesting in combination while maintaining a daily diet.
本発明者らは、以上の状況を鑑み、腎機能の低下抑制を目的として日常の食生活で手軽に摂取できる素材について検討を重ねた結果、キノコ類から得られる抽出物、特に担子菌類ヒダナシタケ目に属するキノコ、さらに限定するならばマイタケから得られる抽出物に腎機能低下抑制効果があることを見出し、本発明に至った。 In view of the above situation, the present inventors have repeatedly studied on materials that can be easily ingested in daily diets for the purpose of suppressing the decrease in renal function, and as a result, extracts obtained from mushrooms, especially basidiomycetes It has been found that an extract obtained from mushrooms belonging to the group No. 2 and, more specifically, maitake mushrooms, has an inhibitory effect on lowering renal function.
上記の課題を解決するための本発明のうち、特許請求の範囲・請求項１に記載する発明は、キノコの水性溶媒抽出物を有効成分として含む腎機能の低下抑制または改善剤である。
Among the present inventions for solving the above-mentioned problems, the invention described in
同請求項２に記載する発明は、水性溶媒抽出の前処理としてキノコの酵素分解を行う請求項１に記載の腎機能の低下抑制または改善剤である。
The invention described in
同請求項３に記載する発明は、キノコが担子菌類ヒダナシタケ目に属する請求項１または２に記載の腎機能の低下抑制または改善剤である。
The invention described in
同請求項４に記載する発明は、キノコの水性溶媒抽出物が多糖、タンパク質、ペプチド、糖タンパク質のいずれか１つ以上を含むキノコの水性溶媒抽出物である請求項１〜３のいずれかに記載の腎機能の低下抑制または改善剤である。
The invention described in
同請求項５に記載する発明は、有効成分としてさらにビタミンＤ類を含む請求項１〜４のいずれかに記載の腎機能の低下抑制または改善剤である。
The invention described in claim 5 is the agent for suppressing or improving renal function deterioration according to any one of
同請求項６に記載する発明は、ビタミンＤ類がキノコ由来である請求項５に記載の腎機能の低下抑制または改善剤である。
The invention described in
同請求項７に記載する発明は、尿酸値の低下、クレアチニン値の低下、尿素窒素値の低下のうち少なくとも１つ以上の効果を有する請求項１〜６のいずれかに記載の腎機能の低下抑制または改善剤である。 The invention described in claim 7 has at least one of the effects of a decrease in uric acid level, a decrease in creatinine level, and a decrease in urea nitrogen level. It is a suppressor or improver.
同請求項８に記載する発明は、キノコの水性溶媒抽出物を有効成分として含む腎機能の低下抑制または改善用食品である。 The invention described in claim 8 is a food for suppressing or improving the decrease in renal function, which contains an aqueous solvent extract of mushrooms as an active ingredient.
同請求項９に記載する発明は、水性溶媒抽出の前処理としてキノコの酵素分解を行う請求項８に記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 9 is the food for suppressing or improving the decrease in renal function according to claim 8, wherein the mushroom is enzymatically decomposed as a pretreatment for extraction with an aqueous solvent.
同請求項１０に記載する発明は、キノコが担子菌類ヒダナシタケ目に属する請求項８または９に記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 10 is the food for suppressing or improving the decrease in kidney function according to claim 8 or 9, wherein the mushroom belongs to the order of the basidiomycete Hidanastake.
同請求項１１に記載する発明は、キノコの水性溶媒抽出物が多糖、タンパク質、ペプチド、糖タンパク質のいずれか１つ以上を含むキノコの水性溶媒抽出物である請求項８〜１０のいずれかに記載の腎機能の低下抑制または改善用食品である。 In the invention described in claim 11, the aqueous solvent extract of mushrooms is an aqueous solvent extract of mushrooms containing any one or more of polysaccharides, proteins, peptides and glycoproteins. The food for suppressing or improving the decrease in renal function as described.
同請求項１２に記載する発明は、有効成分としてさらにビタミンＤ類を含む請求項８〜１１のいずれかに記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 12 is the food for suppressing or improving the decrease in renal function according to any one of claims 8 to 11, further comprising vitamin D as an active ingredient.
同請求項１３に記載する発明は、ビタミンＤ類がキノコ由来である請求項１２に記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 13 is the food for suppressing or improving renal function deterioration according to claim 12, wherein the vitamin D is derived from mushrooms.
同請求項１４に記載する発明は、尿酸値の低下、クレアチニン値の低下、尿素窒素値の低下のうち少なくとも１つ以上の効果を有する請求項８〜１３のいずれかに記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 14 has at least one of the effects of a decrease in uric acid value, a decrease in creatinine value, and a decrease in urea nitrogen value, and a decrease in renal function according to any one of claims 8 to 13. Food for control or improvement.
同請求項１５に記載する発明は、飲料、調理食品、健康食品、機能性食品、特定保健用食品、栄養補助食品、または病者用食品である、請求項８〜１４のいずれかに記載の腎機能の低下抑制または改善用食品である。 The invention described in claim 15 is a beverage, cooked food, health food, functional food, food for specified health use, nutritional supplement, or food for the sick, according to any one of claims 8 to 14. It is a food for suppressing or improving the decrease in renal function.
本発明によって、安全性が高く経口摂取することにより腎機能の低下抑制または改善ができる腎機能の低下抑制または改善用の食品、医薬品を提供することができる。これにより腎不全患者にとっては、透析や腎移植に移行するまでの期間をより遅らせることができ、また腎不全予備軍の人々にとっては日常生活で厳しい食制限を行うことなく腎機能を低下抑制または改善することが期待できる。 According to the present invention, it is possible to provide foods and pharmaceuticals for suppressing or improving renal function that are highly safe and can be suppressed or improved by reducing oral function when taken orally. As a result, for patients with renal failure, the period until transition to dialysis and kidney transplantation can be delayed, and for renal failure reserves, the renal function can be suppressed or reduced without severe food restrictions in daily life. It can be expected to improve.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
本発明の「腎機能の低下抑制または改善剤」には、キノコの水性溶媒抽出物を有効成分として含み、腎機能の低下抑制または改善効果を有する剤であればいずれのものも含まれる。また、本発明の「腎機能の低下抑制または改善用食品」には、キノコの水性溶媒抽出物を有効成分として含み、腎機能の低下抑制または改善効果を有する食品であればいずれのものも含まれる。 The “reducing or reducing agent for renal function” of the present invention includes any agent that contains an aqueous solvent extract of mushrooms as an active ingredient and has an effect of suppressing or improving renal function. Further, the “food for suppressing or improving renal function reduction” of the present invention includes an aqueous solvent extract of mushrooms as an active ingredient, and any food that has an effect of suppressing or improving renal function is included. It is.
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」における「腎機能の低下抑制または改善」とは、腎不全患者または腎不全予備軍とされる人において症状の悪化や合併症の発症を抑制することや、腎臓が本来の機能を発揮し得る状態に近付けること等をいう。例えば、尿酸値、クレアチニン値または尿素窒素値の上昇を抑制することや、これらの値を低下させることが挙げられる。 In the “inhibition or improvement agent for renal function” or “food for suppressing or improving renal function” according to the present invention, “reduction or reduction in renal function” refers to a person who is considered to be a renal failure patient or a renal failure reserve army. This refers to suppressing the worsening of symptoms and the onset of complications, and bringing the kidney close to a state where it can perform its original functions. For example, it is possible to suppress an increase in the uric acid value, creatinine value or urea nitrogen value, or to reduce these values.
本発明における「キノコ」とは担子菌類ヒダナシタケ目（マイタケ、シロマイタケ、ハナビラタケ等を含む）の子実体、その菌糸体および胞子の組み合わせから選択されるキノコを指し、その中でも特にマイタケを用いることが好ましい。 The term “mushroom” as used in the present invention refers to a mushroom selected from the fruiting bodies of the basidiomycete Hydana mushroom (including maitake mushrooms, white mite mushrooms, chanterelle mushrooms, etc.), mycelium and spores, and among them, maitake is particularly used. preferable.
本発明の「キノコの水性溶媒抽出物」はキノコから温水または熱水により抽出されるキノコの水性溶媒抽出物のことをいう。抽出にあたりキノコは原型のまま用いても良いが、より抽出効率を高めるためには破砕し、フレーク状またはペースト状にして用いることが好ましい。破砕の際、原料が高温になると抽出効率が低下するため、原料温度を３０℃以下、好ましくは２０℃以下、より好ましくは１０℃以下に保持するとよい。得られた破砕原料は、そのまま使用してもよいが、場合によっては冷凍保存してもよい。 The “mushroom aqueous solvent extract” of the present invention refers to an aqueous solvent extract of mushrooms extracted from mushrooms with warm water or hot water. In the extraction, the mushrooms may be used as they are, but in order to further increase the extraction efficiency, it is preferable to crush them and use them in the form of flakes or pastes. During the crushing, since the extraction efficiency decreases when the raw material becomes high temperature, the raw material temperature may be maintained at 30 ° C. or lower, preferably 20 ° C. or lower, more preferably 10 ° C. or lower. Although the obtained crushing raw material may be used as it is, it may be stored frozen in some cases.
破砕された原料は、そのまま水を加えて抽出工程に進んでもよいが、前処理として「キノコの酵素分解」を行うと、より抽出効率が上昇するため好ましい。酵素処理には糖質分解酵素を用いることが好ましく、例えば、アミラーゼ、セルラーゼまたはグルコシダーゼ等を用いることができ、これらの酵素を組み合わせて用いることもできる。酵素分解の処理条件は使用する酵素に準じるが、場合によってはさらにカルシウムやナトリウムなどを加えてもよい。酵素液のｐＨは必ずしも調節する必要はないが、通常ｐＨ３．５〜ｐＨ７．５、好ましくはｐＨ６．０〜ｐＨ７．０であることが好ましい。 The crushed raw material may be added to water as it is to proceed to the extraction step, but “enzymatic degradation of mushrooms” as a pretreatment is preferable because the extraction efficiency is further increased. For the enzyme treatment, a saccharide-degrading enzyme is preferably used. For example, amylase, cellulase, glucosidase or the like can be used, and these enzymes can also be used in combination. The treatment conditions for the enzymatic degradation are in accordance with the enzyme used, but in some cases, calcium or sodium may be further added. The pH of the enzyme solution does not necessarily need to be adjusted, but is usually pH 3.5 to pH 7.5, preferably pH 6.0 to pH 7.0.
前処理として酵素分解を行った場合、酵素分解の後、酵素の失活処理を行い、失活処理を行った後、熱水抽出を行うことが好ましい。熱水抽出は従来知られているいずれの方法も用いることができ、場合によって加圧熱水を用いてもよい。熱水抽出後、抽出液を圧搾、遠心分離、ろ過等の方法によって固液分離することが好ましい。抽出液は液体のまま用いることもできるが、フリーズドライ、スプレードライ、ドラムドライ等によって粉末化してもよい。このようにして得られたキノコの水性溶媒抽出物は、多糖、タンパク質、ペプチド、糖タンパク質のいずれか１つ以上を含むものであってもよい。 When enzymatic degradation is performed as a pretreatment, it is preferable to perform enzymatic deactivation after enzymatic degradation, and perform hot water extraction after deactivation. For hot water extraction, any conventionally known method can be used, and in some cases, pressurized hot water may be used. After hot water extraction, the extract is preferably subjected to solid-liquid separation by a method such as pressing, centrifugation, or filtration. The extract can be used as it is, but may be pulverized by freeze drying, spray drying, drum drying or the like. The aqueous solvent extract of mushrooms thus obtained may contain any one or more of polysaccharides, proteins, peptides, and glycoproteins.
本発明の「キノコの水性溶媒抽出物」は、「腎機能の低下抑制または改善剤」や「腎機能の低下抑制または改善用食品」の有効性成分として、これらの剤や食品に配合することができる。それ以外にも抽出液または抽出粉末として、さまざまな食品、医薬品、機能性食品等に配合することができる。配合する食品としては、例えば、健康補助食品等の機能性食品としてだけでなく、飲料、調味料、野菜加工食品、果実加工食品、魚加工食品、肉製品、酪農製品、加工卵製品、香辛料、パン類、菓子類、調理食品、半調理食品、チルド食品、ペットフード等が挙げられる。特に腎不全患者向け調理食品に用いた場合には、患者の腎機能の低下抑制または改善における効果が期待できる。また、本発明の「キノコの水性溶媒抽出物」を配合した食品、医薬品、機能性食品等の製造にあたり、通常の食品等の製造に用いられる、賦形剤、乳化剤、増粘剤、着色料、香料、調味料、香辛料などを適宜配合することもできる。 The “mushroom aqueous solvent extract” of the present invention is incorporated into these agents and foods as an active ingredient of “a food for suppressing or improving renal function” or “a food for suppressing or improving renal function”. Can do. In addition, it can be blended in various foods, pharmaceuticals, functional foods, etc. as an extract or an extracted powder. As food to be blended, for example, not only as functional foods such as health supplements, but also beverages, seasonings, processed vegetable foods, processed fruit foods, processed fish foods, meat products, dairy products, processed egg products, spices, Examples include breads, confectionery, cooked food, semi-cooked food, chilled food, and pet food. In particular, when used in cooked foods for patients with renal failure, an effect in suppressing or improving the decrease in renal function of the patient can be expected. In addition, excipients, emulsifiers, thickeners, colorants used in the production of ordinary foods, etc. in the production of foods, pharmaceuticals, functional foods and the like containing the “mushroom aqueous solvent extract” of the present invention , Fragrances, seasonings, spices, and the like can be appropriately blended.
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」には、キノコの水性溶媒抽出物をそのまま、または他の有効成分とともに含むことができる。
他の有効成分としては、「腎機能の低下抑制または改善」に有効ないずれの成分も含まれるが、例えばビタミンＤが挙げられる。本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」にキノコの水性溶媒抽出物とビタミンＤとを併せて配合することで、腎機能の低下抑制または改善効果がさらに増強される。また、キノコの水性溶媒抽出物のみを有効成分として含む「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」とビタミンＤとを組み合わせて摂取する場合にも腎機能の低下抑制または改善効果が増強される。
The “reducing or reducing agent for renal function” and “food for suppressing or improving renal function” of the present invention can contain an aqueous solvent extract of mushrooms as it is or together with other active ingredients.
Other active ingredients include any ingredient effective for “suppressing or improving the decrease in renal function”, for example, vitamin D. By combining a mushroom aqueous solvent extract and vitamin D together with the “reduction or improvement agent for renal function” or “food for suppressing or improving renal function” of the present invention, The improvement effect is further enhanced. In addition, renal function is also taken when a combination of vitamin D and a “reduction or improvement agent for renal function” containing only an aqueous solvent extract of mushrooms as an active ingredient is combined with vitamin D. The effect of suppressing or improving the decrease is enhanced.
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」に含まれる有効成分の量は、本発明の効果が達成される限り、特に限定はされない。
有効成分としてキノコの水性溶媒抽出物を含む場合には、０．０１重量％〜１００重量％、より好ましくは０．１重量％〜９５重量％含有されるのが好ましい。また、１日の摂取量としては、キノコの水性溶媒抽出物が１０ｍｇ〜５０００ｍｇ、より好ましくは１００ｍｇ〜３０００ｍｇとなるように本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」を摂取するのが好ましい。
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」における、キノコの水性溶媒抽出物の含有量が０．０１重量％を下回ると、本発明の腎機能の低下抑制または改善効果を発揮するためには多量の摂取が必要となるため好ましくない。
The amount of the active ingredient contained in the “reducing or reducing agent for renal function” and “food for suppressing or improving renal function” of the present invention is not particularly limited as long as the effects of the present invention are achieved.
When an aqueous solvent extract of mushroom is included as an active ingredient, it is preferably contained in an amount of 0.01% to 100% by weight, more preferably 0.1% to 95% by weight. In addition, the daily intake is 10 mg to 5000 mg, more preferably 100 mg to 3000 mg of the aqueous mushroom extract, more preferably 100 mg to 3000 mg. It is preferable to take “suppressed or improved food”.
When the content of the aqueous solvent extract of mushrooms in the “agent for suppressing or improving renal function decrease” or “food for suppressing or improving renal function” of the present invention is less than 0.01% by weight, the kidney of the present invention It is not preferable because a large amount of ingestion is required in order to exhibit a function lowering suppression or improvement effect.
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」には有効成分以外に他の成分を組み合わせて含むことができる。例えば、ビタミン類、ミネラル類、食物繊維、糖類、多糖類、酵素類、乳酸菌類、γアミノ酪酸、スピルリナ、キチン、キチンキトサン、車前草エキス、タンポポエキス、クニュウル、クミスクチン、海馬、クランベリー、サンボン、シャンピニオンエキス、クレアチン、グルコサミン、コンドロイチン硫酸等を併用できる。 In addition to the active ingredient, the “reducing inhibitor or improving agent for renal function” and the “food for suppressing or improving renal function” of the present invention may contain other components in combination. For example, vitamins, minerals, dietary fiber, saccharides, polysaccharides, enzymes, lactic acid bacteria, γ-aminobutyric acid, spirulina, chitin, chitin chitosan, car anthracnose extract, dandelion extract, kunuur, cumistin, hippocampus, cranberry, sunbon, champignon Extracts, creatine, glucosamine, chondroitin sulfate, etc. can be used in combination.
本発明の「腎機能の低下抑制または改善剤」、「腎機能の低下抑制または改善用食品」は、その効果を損なわない限り、種々の剤形に製剤化することができる。剤形としては、錠剤、顆粒剤、細粒剤、散剤、カプセル剤、丸剤等の経口用固形製剤のほか、溶液剤、懸濁剤、乳剤などの経口液体製剤が挙げられる。またその際、添加剤、例えば賦形剤、安定剤、防腐剤、湿潤剤、乳化剤、滑沢剤、甘味料、着色料、香料、張度調製剤、緩衝剤、酸化防止剤、ｐＨ調整剤等を併用して製剤化することができる。
本発明の「腎機能の低下抑制または改善用食品」には、いずれの飲食品も含まれるが、例えば飲料、調理食品、健康食品、機能性食品、特定保健用食品、栄養補助食品、または病者用食品等が挙げられる。
以下に本発明の実施例、試験例等を示すが、本発明はこれらのみに限定されるものではない。
The “reducing or reducing agent for renal function” and “food for suppressing or improving renal function” of the present invention can be formulated into various dosage forms as long as the effect is not impaired. Examples of the dosage form include oral solid preparations such as tablets, granules, fine granules, powders, capsules and pills, and oral liquid preparations such as solutions, suspensions and emulsions. In addition, additives such as excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, coloring agents, fragrances, tonicity adjusting agents, buffers, antioxidants, pH adjusting agents. Etc. can be formulated together.
The “food for suppressing or improving the decrease in renal function” of the present invention includes any food and drink, for example, beverages, cooked foods, health foods, functional foods, foods for specified health use, dietary supplements, or diseases. Foods for consumers.
Examples of the present invention, test examples and the like are shown below, but the present invention is not limited to these.
＜キノコの水性溶媒抽出物の製造＞
生マイタケＩＭ−ＢＭ１１号（種苗法に基づく品種出願番号：第１７６０３号）１ｋｇに３倍重量の水を加えアミラーゼを対マイタケ重量比で０．１２％、セルラーゼを対マイタケ重量比で０．０３％添加し、４０℃６時間加温した後、９０℃２時間熱水抽出を行った。熱水抽出後、固液分離し、マイタケの水性溶媒抽出物を得た。
<Production of Mushroom Aqueous Solvent Extract>
Raw maitake IM-BM11 (variety application number based on the seedling method: No. 17603) Three times the weight of water was added to 1 kg, amylase was 0.12% by weight of maitake, and cellulase was 0.03 by weight of maitake. % And heated at 40 ° C. for 6 hours, followed by hot water extraction at 90 ° C. for 2 hours. After hot water extraction, solid-liquid separation was performed to obtain an aqueous solvent extract of maitake.
＜キノコの水性溶媒抽出物の製造＞
生マイタケＩＭ−ＢＭ１１号（種苗法に基づく品種出願番号：第１７６０３号）１ｋｇに３倍重量の水を加えアミラーゼを対マイタケ重量比で０．１％、グルコシダーゼを対マイタケ重量比で０．１％添加し、４０℃６時間加温した後、９０℃２時間熱水抽出を行った。熱水抽出後、固液分離し、マイタケの水性溶媒抽出物を得た。
<Production of Mushroom Aqueous Solvent Extract>
Raw Maitake IM-BM11 (variety application number based on seedling method: No. 17603) 3 kg of water was added to 1 kg, amylase was 0.1% by weight of maitake, and glucosidase was 0.1 by weight of maitake. % And heated at 40 ° C. for 6 hours, followed by hot water extraction at 90 ° C. for 2 hours. After hot water extraction, solid-liquid separation was performed to obtain an aqueous solvent extract of maitake.
＜腎機能の低下抑制または改善剤の製造＞
実施例１で製造したマイタケの水性溶媒抽出物を用い、水と植物性グリセリンを混合し、マイタケの水性溶媒抽出物の固形分換算として１．５ｇ含むペーストを作製し、殺菌した。これをアルミパウチに充填し、腎機能の低下抑制または改善剤を製造した。
<Manufacture of agents for suppressing or improving renal function deterioration>
Using the maitake aqueous solvent extract produced in Example 1, water and vegetable glycerin were mixed to prepare a paste containing 1.5 g as a solid content of the maitake aqueous solvent extract and sterilized. This was filled in an aluminum pouch to produce an agent for suppressing or improving the decrease in renal function.
＜腎機能の低下抑制または改善剤の製造＞
実施例１で製造したマイタケの水性溶媒抽出物を用い、デキストリン、カルシウム（ユニテックフーズ社「ミルクカルシウム２８」）、コーンスターチ、菜種硬化油、ステアリン酸カルシウムを適当量配合して１粒３８０ｍｇのタブレットとすることで、腎機能の低下抑制または改善剤を製造した。この腎機能の低下抑制または改善剤には、マイタケの水性溶媒抽出物が１０粒で５００ｍｇ含まれるように配合した。
<Manufacture of agents for suppressing or improving renal function deterioration>
Using an aqueous solvent extract of maitake prepared in Example 1, dextrin, calcium (Unitech Foods "Milk Calcium 28"), corn starch, hardened rapeseed oil and calcium stearate are mixed in an appropriate amount to give a tablet of 380 mg per tablet. Thus, an agent for suppressing or improving the decrease in renal function was produced. This agent for suppressing or improving the decrease in renal function was formulated so that 10 mg of an aqueous solvent extract of maitake was included in 500 mg.
＜腎機能の低下抑制または改善剤の製造＞
実施例１で製造したマイタケの水性溶媒抽出物を用い、ビタミンＤ、デキストリン、カルシウム（ユニテックフーズ社「ミルクカルシウム２８」）、コーンスターチ、菜種硬化油、ステアリン酸カルシウムを適当量配合して１粒３８０ｍｇのタブレットとすることで、腎機能の低下抑制または改善剤を製造した。この腎機能の低下抑制または改善剤には、マイタケの水性溶媒抽出物が１０粒で５００ｍｇ、ビタミンＤが１０粒で６７０ＩＵ含まれるようにそれぞれ配合した。
<Manufacture of agents for suppressing or improving renal function deterioration>
Using an aqueous solvent extract of maitake prepared in Example 1, vitamin D, dextrin, calcium (Unitech Foods “Milk Calcium 28”), corn starch, rapeseed hardened oil, calcium stearate in an appropriate amount and 380 mg of 1 capsule By using a tablet, an agent for suppressing or improving the decrease in renal function was produced. The agent for suppressing or improving the decrease in renal function was formulated so that 10 mg of an aqueous solvent extract of maitake was included and 670 IU was included in 10 tablets of vitamin D.
［試験例１］
人介入試験（１）
１．試験サンプル
実施例３で製造した腎機能の低下抑制または改善剤を用いた。
[Test Example 1]
Human intervention test (1)
1. Test sample The agent for suppressing or improving the decrease in renal function produced in Example 3 was used.
２．試験方法
成人男性（平均年齢５０歳）３０人を対象に試験を実施した。上記１．の試験サンプルを１日１包ずつ、３５日間摂取させ、試験前後において血液検査を実施した。
2. Test Method A test was conducted on 30 adult males (average age 50 years). Above 1. Each test sample was ingested once a day for 35 days, and blood tests were conducted before and after the test.
３．試験結果
・クレアチニン値の変化
クレアチニン値は試験期間後に減少傾向が認められた（図１）。この減少傾向は有意水準０．０１％で有意であった。
3. Test results-Change in creatinine value The creatinine value tended to decrease after the test period (Fig. 1). This decreasing trend was significant at the significance level of 0.01%.
［試験例２］
人介入試験（２）
１．試験サンプル
実施例４で製造した腎機能の低下抑制または改善剤を用いた。
[Test Example 2]
Human intervention test (2)
1. Test sample The renal function decrease inhibitory or ameliorating agent produced in Example 4 was used.
２．試験方法
成人女性（平均年齢６２歳）２１名を対象に試験を実施した。上記１．の試験サンプルを１日１０粒ずつ、６ヶ月間摂取させ、試験前、試験開始１ヵ月後、試験終了時のそれぞれにおいて血液検査を実施した。
2. Test Method The test was conducted on 21 adult women (average age 62 years). Above 1. The test samples were ingested 10 tablets a day for 6 months, and blood tests were performed before the test, 1 month after the start of the test, and at the end of the test.
３．試験結果
・クレアチニン値の変化
クレアチニン値は試験期間１ヵ月後では変化が認められなかったが、６ヵ月後においては減少傾向が認められた（表１、図２）。この減少傾向は有意水準０．０５％で有意であった。
・尿酸値、尿素窒素値の変化
尿酸値および尿素窒素値は全体では有意差が認められなかったものの値は低下傾向にあった。なお、尿素窒素値１７ｍｇ／ｄｌ以上のやや高値群では６ヵ月後の減少傾向が有意水準０．０５％で有意であった（表２）。
3. Test results-Change in creatinine level The creatinine level did not change after 1 month of the test, but decreased after 6 months (Table 1, Fig. 2). This decreasing trend was significant at the significance level of 0.05%.
・ Changes in uric acid levels and urea nitrogen levels Although uric acid levels and urea nitrogen levels were not significantly different overall, the values tended to decrease. In the slightly higher value group with a urea nitrogen value of 17 mg / dl or more, the decreasing trend after 6 months was significant at a significance level of 0.05% (Table 2).
［試験例３］
人介入試験（３）
１．試験サンプル
実施例５で製造した腎機能の低下抑制または改善剤を用いた。
[Test Example 3]
Human intervention test (3)
1. Test sample The renal function lowering inhibitor or amelioration agent produced in Example 5 was used.
２．試験方法
成人女性（平均年齢６３歳）２５名を対象に試験を実施した。上記１．の試験サンプルを１日１０粒ずつ、６ヶ月間摂取させ、試験前、試験開始１ヵ月後、試験終了時のそれぞれにおいて血液検査を実施した。
2. Test Method A test was conducted on 25 adult women (average age 63 years). Above 1. The test samples were ingested 10 tablets a day for 6 months, and blood tests were performed before the test, 1 month after the start of the test, and at the end of the test.
３．試験結果
・クレアチニン値の変化
クレアチニン値は試験期間１ヵ月後では変化が認められなかったが、６ヵ月後においては減少傾向が認められた（表３、図３）。この減少傾向は有意水準０．０５％で有意であった。
・尿素窒素値の変化
尿素窒素値は試験開始から減少傾向にあり、６ヵ月後においても減少傾向が認められた（表３、図４）。この減少傾向は有意水準０．０５％で有意であった。
・尿酸値の変化
尿酸値は試験開始から１ヵ月後はやや上昇傾向にあったが、６ヵ月後では減少傾向が認められた（表３、図５）。この減少傾向は有意水準０．０１％で有意であった。
3. Test results-Change in creatinine level The creatinine level did not change after 1 month of the test, but decreased after 6 months (Table 3, Fig. 3). This decreasing trend was significant at the significance level of 0.05%.
-Change in urea nitrogen value The urea nitrogen value has been on a decreasing trend since the start of the test, and a decreasing trend was also observed after 6 months (Table 3, Fig. 4). This decreasing trend was significant at the significance level of 0.05%.
・ Changes in uric acid levels Uric acid levels tended to increase slightly one month after the start of the test, but decreased after six months (Table 3, Fig. 5). This decreasing trend was significant at the significance level of 0.01%.
以上の結果より、本発明のキノコの水性溶媒抽出物を有効成分として含む腎機能の低下抑制または改善剤には、腎機能の低下抑制または改善効果があることが確認された。さらに本発明のキノコの水性溶媒抽出物を有効成分として含む腎機能の低下抑制または改善剤にビタミンＤを併せて配合することで、その効果がさらに増強されることが示された。 From the above results, it was confirmed that the renal function reduction inhibitor or ameliorating agent containing the mushroom aqueous solvent extract of the present invention as an active ingredient has a renal function reduction inhibitory or improvement effect. Furthermore, it was shown that the effect is further enhanced by combining vitamin D with an agent for suppressing or improving the decrease in renal function containing the mushroom aqueous solvent extract of the present invention as an active ingredient.
＜腎機能の低下抑制または改善用食品（粉末スープ）の製造＞
配合組成として、コーンパウダー３５％、脱脂粉乳２５％、澱粉２６％、オニオンパウダー８．３９％、実施例２で製造したマイタケ水性溶媒抽出物１％、ビタミンＤ（０．５％含有品）０．０１％、風味補強剤０．３％、乳化剤０．３％、食塩３％および粉末ブイヨン１％の混合物を調整後、造粒機を用いて顆粒状に加工した。これをアルミ三方スティックに２０ｇずつ充填し、腎機能の低下抑制または改善用食品として粉末スープを製造した。このようにして製造した粉末スープ１袋をお湯２００ｇに溶かしたところ、適度な塩味とうま味を有していた。
<Manufacture of food (powder soup) for suppression or improvement of renal function>
As a blending composition, corn powder 35%, skim milk powder 25%, starch 26%, onion powder 8.39%, maitake aqueous solvent extract produced in Example 2, 1% vitamin D (0.5% content) 0 A mixture of 0.01%, flavor enhancer 0.3%, emulsifier 0.3%,
本発明により得られる腎機能の低下抑制または改善剤、腎機能の低下抑制または改善用食品は、摂取により腎機能関連の数値が有意に改善されたことから、腎不全患者の腎機能の低下抑制のみならず、腎不全予備軍とされる人々の腎機能の低下抑制または改善に非常に有用であり、その産業的価値は大きい。 The agent for suppressing or improving renal function obtained according to the present invention, the food for suppressing or improving renal function, since the value related to renal function was significantly improved by ingestion. In addition, it is very useful for suppressing or improving the decrease in renal function of people regarded as having a renal failure reserve, and its industrial value is great.
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008083019A JP2009234984A (en) | 2008-03-27 | 2008-03-27 | Agent for inhibition of lowering or for ameliorating renal function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008083019A JP2009234984A (en) | 2008-03-27 | 2008-03-27 | Agent for inhibition of lowering or for ameliorating renal function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2009234984A true JP2009234984A (en) | 2009-10-15 |
Family
ID=41249406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008083019A Withdrawn JP2009234984A (en) | 2008-03-27 | 2008-03-27 | Agent for inhibition of lowering or for ameliorating renal function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2009234984A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578443A (en) * | 2018-03-05 | 2018-09-28 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
| JP7479090B1 (en) | 2023-01-06 | 2024-05-08 | 学校法人関西文理総合学園 | Renal function improver |
-
2008
- 2008-03-27 JP JP2008083019A patent/JP2009234984A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578443A (en) * | 2018-03-05 | 2018-09-28 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
| JP7479090B1 (en) | 2023-01-06 | 2024-05-08 | 学校法人関西文理総合学園 | Renal function improver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102665725B (en) | Agent for improving hyperlipidemia, composition for improving anemia, composition for reducing uric acid level, and food and drink | |
| CN111602720A (en) | Formula milk powder for middle-aged and old people | |
| KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
| CN107319524A (en) | A kind of nephrosis tailored version clinical nutrition formula and preparation method thereof | |
| TW201943417A (en) | Food composition for cognitive function improvement, cognitive function improving agent, and production method thereof characterized by containing L-ergothioneine as an active ingredient | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| JP5594819B2 (en) | Composition for improving lipid metabolism | |
| US20190134165A1 (en) | Compositions and methods for treating thyroid disease | |
| CN103610171B (en) | Kelp beverage and preparation method thereof | |
| JP2011148748A (en) | Adiponectin secretion-promoting composition | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| JP5156330B2 (en) | Adipose tissue weight reducing agent | |
| JP2007217366A (en) | Composition for lowering uric acid level | |
| JP2009234984A (en) | Agent for inhibition of lowering or for ameliorating renal function | |
| JP2004000171A (en) | Functional food product containing maca | |
| KR20060024766A (en) | Disease improvement foods to reduce the concentration of low molecular weight nitrogen-containing compounds in the blood | |
| JP2005170836A (en) | Seaweed extract and lipase inhibitor containing the same | |
| KR20200043555A (en) | Supplement food composition for diet | |
| KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
| JP2007008920A (en) | Lifestyle-related disease-improving agent | |
| EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
| JP4673071B2 (en) | Iron-adsorptive polymer substance, iron-containing polymer substance, and production method thereof | |
| JP2009034017A (en) | Diet food | |
| KR100734944B1 (en) | Functional health food composition based on calcium lactate and rice bran | |
| JP2008120771A (en) | Ameliorating agent for constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20110607 |